Fathom Frontier briefings, made easy.
Subscribe
← All Biotech briefings

Biotech

Artiva shuts down after two deaths in cell therapy trial

2026-10-28

Artiva Biotherapeutics has dropped its NK cell therapy and laid off 94% of its staff. The San Diego biotech announced it Oct. 27, after two patients died in a Phase 2a trial. The therapy, AlloNK, was being tested in rheumatoid arthritis and other autoimmune diseases. Artiva is now exploring options, including possible dissolution. Shares fell about 34%.

AlloNK is an off-the-shelf cell therapy. That means it is made in advance instead of for each patient. It uses natural killer cells, a type of immune cell. The first death was a fatal neurological event after treatment. The FDA, investigators and a safety monitoring board asked Artiva to pause enrollment and dosing. Artiva also paused plans for a Phase 3 trial. The second patient died about two months after treatment began. The investigator judged that death unrelated to AlloNK. Its cause is still undetermined. Fierce Biotech reports weak durability data also hurt. Durability means how long a treatment keeps working.

Keep reading — what to watch

Will other cell therapies for autoimmune disease face the same scrutiny? STAT calls this the latest in a series of safety events in a promising field. That raises a fair question for companies still running trials. Watch what Artiva does next. It said it is weighing strategic options, including dissolution. Watch the second patient's cause of death too. If it turns out unrelated, the case against the therapy gets murkier.

Sources

Fierce Biotech — Artiva lays off 94% of staff after deaths and durability sink autoimmune cell therapy BioSpace — After 2 patient deaths and cell therapy durability concerns, Artiva cuts 94% of workforce MedCity News — Patients Deaths and Data Shortfall Spell the End for Cell Therapy Biotech Artiva STAT — After two deaths in autoimmune cell therapy trial, Artiva is shutting down

This story is written by AI from the sources above, checked against them before publishing. If something here still reads wrong, tell us and we'll correct it.

← Crypto Energy →